Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales of ordinary shares tied to rollover/compensation transactions and prior dispositions. The filing lists multiple lot sizes dated 03/03/2026 and 03/04/2026, including quantities of 24,900, 33,512, and 23,251 shares. The excerpt also shows 153,251 shares sold during the past three months on 05/14/2026 for $5,457,368.64. The filing names Citigroup Global Markets as a broker and identifies the transactions as compensation ordinary shares or shares from rollover.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales of ordinary shares tied to rollover/compensation transactions and prior dispositions. The filing lists multiple lot sizes dated 03/03/2026 and 03/04/2026, including quantities of 24,900, 33,512, and 23,251 shares. The excerpt also shows 153,251 shares sold during the past three months on 05/14/2026 for $5,457,368.64. The filing names Citigroup Global Markets as a broker and identifies the transactions as compensation ordinary shares or shares from rollover.
Teva Pharmaceutical Industries director Sol J. Barer exercised 21,739 restricted share units into ordinary shares. The RSUs were granted on June 5, 2025 and vested on June 5, 2026, resulting in delivery of 21,739 ordinary shares at a stated price of $0.00 per share.
Following this vesting and conversion, Barer directly holds 448,011 ordinary shares. The transaction reflects a compensation-related derivative exercise with no reported open-market buying or selling. The ordinary shares may also be represented by American Depositary Shares, each currently equal to one ordinary share.
Teva Pharmaceutical Industries director Sol J. Barer exercised 21,739 restricted share units into ordinary shares. The RSUs were granted on June 5, 2025 and vested on June 5, 2026, resulting in delivery of 21,739 ordinary shares at a stated price of $0.00 per share.
Following this vesting and conversion, Barer directly holds 448,011 ordinary shares. The transaction reflects a compensation-related derivative exercise with no reported open-market buying or selling. The ordinary shares may also be represented by American Depositary Shares, each currently equal to one ordinary share.
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.
The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.
The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.
TEVA Pharmaceutical Industries director Rosemary A. Crane exercised 14,492 restricted share units into ordinary shares. The Form 4 shows she acquired 14,492 ordinary shares on June 5, 2026 through the conversion of vested restricted share units at a stated price of $0.00 per share.
Following this transaction, Crane directly holds 127,739 ordinary shares. The derivative position associated with these 14,492 restricted share units is now fully settled, with no remaining units from this grant. The footnotes state that each restricted share unit represented a contingent right to receive one ordinary share or its cash value and that the units were granted on June 5, 2025 and vested on June 5, 2026.
TEVA Pharmaceutical Industries director Rosemary A. Crane exercised 14,492 restricted share units into ordinary shares. The Form 4 shows she acquired 14,492 ordinary shares on June 5, 2026 through the conversion of vested restricted share units at a stated price of $0.00 per share.
Following this transaction, Crane directly holds 127,739 ordinary shares. The derivative position associated with these 14,492 restricted share units is now fully settled, with no remaining units from this grant. The footnotes state that each restricted share unit represented a contingent right to receive one ordinary share or its cash value and that the units were granted on June 5, 2025 and vested on June 5, 2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at a stated price of $0.00 per share.
After this non-cash equity compensation event, Elstein directly held 2,118,455 ordinary shares. Each restricted share unit provided a contingent right to receive one ordinary share or, at the company committee’s option, the cash value of one ordinary share. No open-market buy or sell transaction was reported in this filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at a stated price of $0.00 per share.
After this non-cash equity compensation event, Elstein directly held 2,118,455 ordinary shares. Each restricted share unit provided a contingent right to receive one ordinary share or, at the company committee’s option, the cash value of one ordinary share. No open-market buy or sell transaction was reported in this filing.
Teva Pharmaceutical Industries director Gerald M. Lieberman exercised restricted share units into ordinary shares. On June 5, 2026, he acquired 14,492 ordinary shares at a stated price of $0.00 per share through the vesting and conversion of restricted share units granted on June 5, 2025.
Following this transaction, he directly holds 130,149 ordinary shares. The footnotes note that each restricted share unit entitled him, at settlement, to receive one ordinary share or the cash value of one ordinary share, and that ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries director Gerald M. Lieberman exercised restricted share units into ordinary shares. On June 5, 2026, he acquired 14,492 ordinary shares at a stated price of $0.00 per share through the vesting and conversion of restricted share units granted on June 5, 2025.
Following this transaction, he directly holds 130,149 ordinary shares. The footnotes note that each restricted share unit entitled him, at settlement, to receive one ordinary share or the cash value of one ordinary share, and that ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were settled into 14,492 ordinary shares, bringing Perry’s direct holdings to 119,807 ordinary shares.
Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were settled into 14,492 ordinary shares, bringing Perry’s direct holdings to 119,807 ordinary shares.
Teva Pharmaceutical Industries director Ronit Satchi-Fainaro exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units converted into 14,492 ordinary shares at a stated exercise price of $0.00 per unit, reflecting RSU vesting rather than an open-market purchase.
These RSUs were originally granted on June 5, 2025 and vested on June 5, 2026. After the settlement, Satchi-Fainaro directly holds 112,401 ordinary shares. The filing shows an acquisition of shares through equity compensation, with no reported open-market buying or selling.
Teva Pharmaceutical Industries director Ronit Satchi-Fainaro exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units converted into 14,492 ordinary shares at a stated exercise price of $0.00 per unit, reflecting RSU vesting rather than an open-market purchase.
These RSUs were originally granted on June 5, 2025 and vested on June 5, 2026. After the settlement, Satchi-Fainaro directly holds 112,401 ordinary shares. The filing shows an acquisition of shares through equity compensation, with no reported open-market buying or selling.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.
Teva Pharmaceutical Industries director Roberto Mignone reported exercising restricted share units into 14,492 Ordinary Shares on June 5, 2026, at a stated price of $0.00 per share. Following this, he directly holds 119,807 Ordinary Shares.
A separate 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd., advised by Bridger Management, LLC, which Mignone manages. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.
Teva Pharmaceutical Industries director Roberto Mignone reported exercising restricted share units into 14,492 Ordinary Shares on June 5, 2026, at a stated price of $0.00 per share. Following this, he directly holds 119,807 Ordinary Shares.
A separate 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd., advised by Bridger Management, LLC, which Mignone manages. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.